REGENXBIO settles Penn sublicense fees with $8M payment and $12M over 4 years; future fees removed

REGENXBIO Inc.

Company pays $8.0M to Penn for sublicense fees related to AbbVie collaboration agreement.
Company will pay $12.0M over four years ($3M annually) to satisfy past/future sublicense obligations.
Letter agreement deletes Section 3.5 of Penn-REGENXBIO License, removing obligation to pay future sublicense fees.
Penn gains right to conduct gene therapy research outside a single identified field, with no restriction.
Parties agree to explore further expansion of relationship, including new collaboration and alliance opportunities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.